Suppr超能文献

新型磺酰苯胺类化合物作为乳腺癌抗增殖剂的合成与生物学评价

Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.

作者信息

Su Bin, Darby Michael V, Brueggemeier Robert W

机构信息

Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, 500 West 12th Avenue, The Ohio State University, Columbus, OH 43210, USA.

出版信息

J Comb Chem. 2008 May-Jun;10(3):475-83. doi: 10.1021/cc700138n. Epub 2008 Apr 2.

Abstract

Combinatorial chemistry approaches facilitate drug discovery processes and result in structural modifications of lead compounds that enhance pharmacological activity, improve pharmacokinetic properties, or reduce unwanted side effects. Epidemiological and animal model studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) can act as chemopreventive agents. The cyclooxygenase-2 (COX-2) inhibitor nimesulide shows anticancer effects in several cancer cell lines via COX-2-dependent and -independent mechanisms. The molecular structure of nimesulide was used as a starting scaffold to design novel sulfonanilide analogs and examine the structural features that contribute to this anticancer effect. A systematic combinatorial chemical approach was used to generate diversely substituted sulfonanilide derivatives that were tested for their effects on the proliferation of human breast cancer cells. Structure-function analysis indicated that the inhibition of cell growth by compounds derived from the novel sulfonanilides required a bulky terminal phenyl ring, a methanesulfonamide, and a hydrophobic carboxamide moiety.

摘要

组合化学方法有助于药物发现过程,并导致先导化合物的结构修饰,从而增强药理活性、改善药代动力学性质或减少不良副作用。流行病学和动物模型研究表明,非甾体抗炎药(NSAIDs)可作为化学预防剂。环氧化酶-2(COX-2)抑制剂尼美舒利通过COX-2依赖性和非依赖性机制在几种癌细胞系中显示出抗癌作用。尼美舒利的分子结构被用作起始支架,以设计新型磺酰苯胺类似物,并研究促成这种抗癌作用的结构特征。采用系统的组合化学方法生成了多种取代的磺酰苯胺衍生物,并测试了它们对人乳腺癌细胞增殖的影响。结构-功能分析表明,新型磺酰苯胺衍生化合物对细胞生长的抑制需要一个庞大的末端苯环、一个甲磺酰胺和一个疏水的甲酰胺部分。

相似文献

1
Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer.
J Comb Chem. 2008 May-Jun;10(3):475-83. doi: 10.1021/cc700138n. Epub 2008 Apr 2.
2
Selective regulation of aromatase expression for drug discovery.
J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):207-10. doi: 10.1016/j.jsbmb.2009.11.009. Epub 2009 Dec 1.
3
Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6733-5. doi: 10.1016/j.bmcl.2009.09.109. Epub 2009 Oct 3.
6
New nimesulide derivatives with amide/sulfonamide moieties: Selective COX-2 inhibition and antitumor effects.
Eur J Med Chem. 2021 Oct 5;221:113566. doi: 10.1016/j.ejmech.2021.113566. Epub 2021 May 24.
8
Design and synthesis of a biotinylated probe of COX-2 inhibitor nimesulide analog JCC76.
Bioorg Med Chem Lett. 2011 Sep 15;21(18):5324-7. doi: 10.1016/j.bmcl.2011.07.025. Epub 2011 Jul 14.
9
Synthesis, antiproliferative activities and in vitro biological evaluation of novel benzofuransulfonamide derivatives.
Bioorg Med Chem Lett. 2011 Sep 15;21(18):5389-92. doi: 10.1016/j.bmcl.2011.07.007. Epub 2011 Jul 13.
10
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
J Med Chem. 2007 Apr 5;50(7):1635-44. doi: 10.1021/jm061133j. Epub 2007 Feb 22.

引用本文的文献

2
Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors.
J Med Chem. 2013 Jul 11;56(13):5306-20. doi: 10.1021/jm4004736. Epub 2013 Jun 28.
3
Identification of selective tubulin inhibitors as potential anti-trypanosomal agents.
Bioorg Med Chem Lett. 2012 Sep 1;22(17):5508-16. doi: 10.1016/j.bmcl.2012.07.023. Epub 2012 Jul 14.
4
Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.
Future Med Chem. 2012 Mar;4(3):361-83. doi: 10.4155/fmc.11.177.
5
From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.
Eur J Med Chem. 2012 Jan;47(1):432-444. doi: 10.1016/j.ejmech.2011.11.012. Epub 2011 Nov 15.
6
COX-2 inhibitor nimesulide analogs are aromatase suppressors in breast cancer cells.
J Steroid Biochem Mol Biol. 2010 Oct;122(4):232-8. doi: 10.1016/j.jsbmb.2010.06.004. Epub 2010 Jun 11.
7
Selective regulation of aromatase expression for drug discovery.
J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):207-10. doi: 10.1016/j.jsbmb.2009.11.009. Epub 2009 Dec 1.
8
Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.
Bioorg Med Chem Lett. 2009 Dec 1;19(23):6733-5. doi: 10.1016/j.bmcl.2009.09.109. Epub 2009 Oct 3.

本文引用的文献

1
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells.
J Med Chem. 2007 Apr 5;50(7):1635-44. doi: 10.1021/jm061133j. Epub 2007 Feb 22.
2
Risks and benefits of celecoxib to prevent recurrent adenomas.
N Engl J Med. 2006 Aug 31;355(9):950-2. doi: 10.1056/NEJMe068158.
5
COX inhibitors and breast cancer.
Br J Cancer. 2006 Feb 13;94(3):346-50. doi: 10.1038/sj.bjc.6602942.
6
Aromatase inhibitors in the treatment of breast cancer.
Endocr Rev. 2005 May;26(3):331-45. doi: 10.1210/er.2004-0015. Epub 2005 Apr 6.
7
Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.
J Clin Endocrinol Metab. 2005 May;90(5):2563-70. doi: 10.1210/jc.2004-2029. Epub 2005 Feb 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验